Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows

Researchers at Case Western Reserve University School of Medicine have discovered that Novo Nordisk A/S’ (NYSE:NVO) semaglutide, an ingredient for a well-known diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D) when compared to seven other anti-diabetic medications.

Alzheimer’s is a progressive brain disorder that impairs memory and cognitive function.

According to the Alzheimer’s Association, nearly 7 million Americans aged 65 and older are living with the condition, and it causes more deaths than breast and prostate cancer combined.

Alzheimer’s disease, which leads to the deaths of about 120,000 Americans annually, is the seventh-leading cause of death in the U.S., according to the CDC.

The study revealed that T2D patients taking semaglutide had a notably lower risk of developing Alzheimer’s, regardless of factors like obesity, gender, or age.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist that ...